03Jun 2022
Efficacy and safety of a basal insulin + 2‐3 oral antihyperglycaemic drugs regimen versus a twice‐daily premixed insulin + metformin regimen after short‐term intensive insulin therapy in individuals with type 2 diabetes: the multicentre, open‐label, randomised controlled BEYOND‐V trial

Efficacy and safety of a basal insulin + 2‐3 oral antihyperglycaemic drugs regimen versus a twice‐daily premixed insulin + metformin regimen after short‐term intensive insulin therapy in individuals with type 2 diabetes: the multicentre, open‐label, randomised controlled BEYOND‐V trial

To compare the efficacy and safety of basal insulin glargine 100 units/mL (Gla) + 2‐3 oral antihyperglycaemic drugs (OADs) with twice‐daily premixed insulin aspart 70/30 (Asp30) + metformin (MET) after short‐term intensive insulin therapy in adults with type 2 diabetes in China. Compared with Asp30 + MET, Gla +2‐3 OADs showed similar efficacy but lower hypoglycaemia risk in Chinese individuals with type 2 diabetes who had undergone short‐term intensive insulin therapy.

  • #endo-diabetology

Like

Save

Share